About: Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response
Creator	Shi, Pei-Yong Alter, Galit Suthar, Mehul Menachery, Vineet Cheedarla, Narayanaiah Kishore, Nanda Atyeo, Caroline Fischinger, Stephanie Rahman, Abdul Rao, Rama Floyd, Katharine Gangadhara, Sailaja Sahoo, Anusmita Shiferaw, Ayalnesh
Source	BioRxiv
abstract	There is a great need for the development of vaccines for preventing SARS-CoV-2 infection and mitigating the COVID-19 pandemic. Here, we developed two modified vaccinia Ankara (MVA) based vaccines which express either a membrane anchored full-length spike protein (MVA/S) stabilized in a prefusion state or the S1 region of the spike (MVA/S1) which forms trimers and is secreted. Both immunogens contained the receptor-binding domain (RBD) which is a known target of antibody-mediated neutralization. Following immunizations with MVA/S or MVA/S1, both spike protein recombinants induced strong IgG antibodies to purified full-length SARS-CoV-2 spike protein. The MVA/S induced a robust antibody response to purified RBD, S1 and S2 whereas MVA/S1 induced an antibody response to the S1 region outside of the RBD region. Both vaccines induced an antibody response in the lung and that was associated with induction of bronchus-associated lymphoid tissue. MVA/S but not MVA/S1 vaccinated mice generated robust neutralizing antibody responses against SARS-CoV-2 that strongly correlated with RBD antibody binding titers. Mechanistically, S1 binding to ACE-2 was strong but reduced following prolonged pre-incubation at room temperature suggesting confirmation changes in RBD with time. These results demonstrate MVA/S is a potential vaccine candidate against SARS-CoV-2 infection.
has issue date	2020-06-27(xsd:dateTime)
bibo:doi	10.1101/2020.06.27.175166
has license	biorxiv
sha1sum (hex)	e10c603a0f5daf2f52628b2dfca43080260e2521
schema:url	https://doi.org/10.1101/2020.06.27.175166
resource representing a document's title	Modified Vaccinia Ankara Based SARS-CoV-2 Vaccine Expressing Full-Length Spike Induces Strong Neutralizing Antibody Response
schema:publication	bioRxiv
resource representing a document's body	covid:e10c603a0f5daf2f52628b2dfca43080260e2521#body_text
is schema:about of	named entity 'confirmation' named entity 'mice' named entity 'reduced' named entity 'infection' named entity 'RBD' named entity 'trimers' named entity 'infection' named entity 'correlated' named entity 'Response' named entity 'Antibody' named entity 'FOLLOWING' named entity 'EXPRESS' named entity 'ROBUST' named entity 'STRONG' named entity 'Both' named entity 'membrane' named entity 'binding' named entity 'secreted' named entity 'neutralizing antibody' named entity 'robust' named entity 'spike' named entity 'RBD' named entity 'antibodies' named entity 'recombinants' named entity 'neutralizing antibody' named entity 'immunizations' named entity 'RBD' named entity 'MVA' named entity 'spike protein' named entity 'antibody response' named entity 'COVID-19 pandemic' named entity 'vaccines' named entity 'MVA' named entity 'RBD' named entity 'mice' named entity 'spike protein' named entity 'MVA' named entity 'MVA' named entity 'membrane anchored' named entity 'MVA' named entity 'SARS-CoV-2' named entity 'primary antibodies' named entity 'antibody' named entity 'titer' named entity 'MVA' named entity 'virus' named entity 'milk powder' named entity 'MVA' named entity 'goat' named entity 'infection' named entity 'IgG' named entity 'monomeric' named entity 'spike protein' named entity 'MVA' named entity 'virus' named entity 'IgG' named entity 'Electron Microscopy' named entity 'mucosal' named entity 'Binding affinity' named entity 'virus' named entity 'Luminex' named entity 'PBS' named entity 'non-human primates' named entity 'Mann-Whitney' named entity 'Luminex' named entity 'Thermo Scientific' named entity 'protein' named entity 'Dana Farber' named entity 'mice' named entity 'ACE2' named entity 'facial vein'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software